News
2 Medical Device Stocks to Buy Hand Over Fist in March
A good way to invest in the healthcare industry's continued growth is by targeting businesses that make medical devices. Such equipment aids physicians in surgery, helps patients recover, and can
2 Biotech Stocks to Buy Hand Over Fist in March
Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF, which tracks an industry
MacroGenics (MGNX) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
MacroGenics (NASDAQ: MGNX)Q4 2023 Earnings CallMar 07, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Why Victoria's Secret Stock Plummeted Today
Shares of Victoria's Secret (NYSE: VSCO) plummeted 29.7% on Thursday after the lingerie, clothing, and beauty-products retailer announced reasonably solid quarterly results but followed with
Why Viking Therapeutics Stock Is Plunging Today
Shares of Viking Therapeutics (NASDAQ: VKTX) were plunging 17.4% lower as of 11:52 a.m. ET on Thursday. This decline wasn't caused by an announcement by Viking. Instead, the sell-off appears to be
1 Wall Street Analyst Thinks Pfizer Stock Is Going to $45. Is It a Buy Around $26?
Per Cantor Fitzgerald analyst Louise Chen's calculations published March 4, Pfizer's (NYSE: PFE) stock is going to climb by around 75% to reach or surpass $45 over the coming quarters. Chen's
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
The day after Intellia Therapeutics (NASDAQ: NTLA) updated investors with its results for the fourth quarter on Feb. 23, Cannacord Genuity analyst Whitney Ijem issued a new price target for the
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?
Just when the weight-loss drug market was heating up, the temperature rose even more. Eli Lilly (NYSE: LLY) is already giving Novo Nordisk (NYSE: NVO) a run for its money with the approval in the
Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter
DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose
A New Competitor to Wegovy Could Be on the Way. Should Novo Nordisk Be Worried?
The weight loss drug market has been one of the most talked-about investing trends over the past year. One of the leaders in this area is Denmark-based Novo Nordisk (NYSE:NVO), thanks to its type 2
3 Biopharma Stocks You Don't Want to Miss in the New Bull Market
It's not always a good idea to chase trends in a bull market, but sometimes the new wave of promising companies is more than a fad. In the biotech and pharma industries, right now is an exciting
Better Weight Loss Drug Stock: Viking Therapeutics vs. Eli Lilly
The gold rush for anti-obesity medicines is here, and the stakes are high. Per a report by Morgan Stanley Research, the market for weight loss drugs will be worth around $77 billion by 2030, despite
Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical evidence supporting the use of Dexcom
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
On Feb. 20, Wedbush financial analyst Andreas Argyrides restated his price target for Sarepta Therapeutics (NASDAQ: SRPT) stock, claiming that its shares would reach $224, rising 73% in the process
1 S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Keep winners, ditch losers. That's usually not bad advice for investors. There's one big problem, though: Sometimes long-term winners temporarily look like losers.
Even the biggest and the best
1 Wall Street Analyst Thinks Viking Therapeutics Stock Is Going to $116. Is It a Buy Around $81?
With shares of Viking Therapeutics (NASDAQ: VKTX) flying 555% higher in the last three months, at least one financial analyst is saying that it can go even higher. On Feb. 28, Oppenheimer's Jay
Is Novavax a Buy Now?
Novavax (NASDAQ: NVAX) has taken investors on a roller coaster ride over the past week or so. The stock soared after the company settled a dispute with a big customer, then sank as it reported
Ozempic Won't Sink This Medical Device Stock's Prospects -- Quite the Opposite
Anti-obesity drugs rose in popularity last year, helping the leaders in this market -- notably Eli Lilly and Novo Nordisk -- crush the market. However, some medical device specialists got the wrong
Better Buy: Eli Lilly vs. Viking Therapeutics
Comparing Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX) might initially seem odd. The two drugmakers don't seem to have much in common. Eli Lilly is more than 50 times the size of
Missed Out on Novo Nordisk Stock? Buy This 1 Biotech Stock Right Now.
After rising by 137% in one day upon the publication of favorable phase 2 clinical trial results on Feb. 27, Viking Therapeutics (NASDAQ: VKTX) is now doubtlessly on many investors' radars. Soon
1 Magnificent S&P 500 Dividend Stock Down 56% to Buy and Hold Forever
Given its key role in the fight against COVID-19, the fact that Pfizer (NYSE: PFE) shares are down 56% from their 2021 peak isn't entirely surprising. Demand for its COVID-19 vaccine (Comirnaty) and
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
On Feb. 20, Cantor Fitzgerald analyst Eric Schmidt restated his aggressive price target for Biogen, (NASDAQ: BIIB) estimating that the biopharmaceutical stock will rise by 39% to reach roughly $311
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
Technically, there is no upper limit to how much money investors can make from stocks in five years, but turning $1,000 into $2,500 is no easy task. That requires a compound annual growth rate
1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?
Since 2021, shares of Novavax (NASDAQ: NVAX) have absolutely crumbled, falling by a whopping 95%. Even with the price rally in recent days, the stock has still been a disastrous investment over the
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Karyopharm Therapeutics (NASDAQ: KPTI)Q4 2023 Earnings CallFeb 29, 2024, 8:00 a.m. ET
Operator
Source Fool.com